UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000001777
Receipt number R000002139
Scientific Title A Phase II trial of neoadjuvant chemotherapy with S-1 and fractional cisplatin for locally advanced gastric cancer
Date of disclosure of the study information 2009/03/16
Last modified on 2009/03/16 00:32:09

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Phase II trial of neoadjuvant chemotherapy with S-1 and fractional cisplatin for locally advanced gastric cancer

Acronym

A Phase II trial of neoadjuvant chemotherapy with S-1 and fractional cisplatin for locally advanced gastric cancer

Scientific Title

A Phase II trial of neoadjuvant chemotherapy with S-1 and fractional cisplatin for locally advanced gastric cancer

Scientific Title:Acronym

A Phase II trial of neoadjuvant chemotherapy with S-1 and fractional cisplatin for locally advanced gastric cancer

Region

Japan


Condition

Condition

Gastric cancer

Classification by specialty

Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate safety and efficacy of neoadjuvant chemotherapy with S-1 plus fractional cisplatin for locally advanced gastric cancer.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Phase II


Assessment

Primary outcomes

Response rate, pathological response

Key secondary outcomes

Over all survival , relapse free survival, curative resection rate, operative complication rate, adverse event


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Chemotherapy and surgery

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >

Gender

Male and Female

Key inclusion criteria

Selection Criteria
1)Pathologically confirmed gastric cancer
2) i)cStageIIIa or IIIb
ii)Borrmann Type III with the maximum tumor diameter of 8cm or more
iii)Borrmann Type IV
3) a case with clinically resectable legion
4) a case with target lesion or measurable lesion
5) No previous treatment
6) Age between 20 and 75 years old when an informed concent was taken.
7) ECOG 0 or 1 Informed concent
8)Biology and biochemistry data are fit for the following criteria within 14 days before registration.
a) WBC &#8805; 3,500/&micro;L
b) PLT &#8805; 100,000/&micro;L
c) Hb &#8805; 9.0 g/dL
d) AST, ALT &#8804; ULN x 2.0
e) T-Bil &#8804; ULN x 2.0
f) CRE &#8804; ULN or CCR &#8805; 50ml/min
9) Patient who can eat orally and is judged to be appropriate for neoadjuvant chemotherapy by the principal investigator
10) written informed consent to participate in the study.

Key exclusion criteria

Exclusion criteria
1)Fresh bleeding from the tumor
2)Paralysis of intestine or ileus
3)Diarrhea(watery stool)
4) Synchronous multicancer
5) infection
6) Interstitial pneumonitis or fibroid lung
7) a large amount of pleural effusion or ascites
8) Jaundice
9)Uncontrollable diabetes mellitus, 10) heart failure requiring the treatment, myocardial infarction within 6 months, uncontrolled arrhythmia or angina
11)Patients pregnant or in lactation, or wish to become pregnant during this study. Male patients who intend to make someone pregnant during this study
12)Patient who has experienced serious drug allergy in the past
13)Patient who is judged to be inappropriate for this study by the principal investigator or the doctors in charge

Target sample size

25


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Iwao Sasaki

Organization

Tohoku University, Graduate School of Medicine

Division name

Division of Biological Regulation and Oncology, Department of Surgery

Zip code


Address

1-1 Seiryo machi, Aoba-ku, Miyagi, Japan

TEL

022-717-7205

Email



Public contact

Name of contact person

1st name
Middle name
Last name Makoto Kinouchi

Organization

Graduate School of Medicine, Tohoku University

Division name

Division of Biological Regulation and Oncology, Department of Surgery

Zip code


Address

1-1 Seiryo machi, Aoba-ku, Miyagi, Japan

TEL

022-717-7205

Homepage URL


Email

kinouchi@surg1.med.tohoku.ac.jp


Sponsor or person

Institute

Division of Biological Regulation and Oncology, Department of Surgery, Graduate School of Medicine, Tohoku University

Institute

Department

Personal name



Funding Source

Organization

Division of Biological Regulation and Oncology, Department of Surgery, Graduate School of Medicine, Tohoku University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2009 Year 03 Month 16 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Date of protocol fixation

2007 Year 04 Month 06 Day

Date of IRB


Anticipated trial start date

2007 Year 05 Month 01 Day

Last follow-up date

2013 Year 04 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2009 Year 03 Month 16 Day

Last modified on

2009 Year 03 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002139


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name